Kiss and Run: Promoting Effective and Targeted Cellular Uptake of a Drug Delivery Vehicle Composed of an Integrin-Targeting Diketopiperazine Peptidomimetic and a Cell-Penetrating Peptide
- PMID: 31243977
- DOI: 10.1021/acs.bioconjchem.9b00292
Kiss and Run: Promoting Effective and Targeted Cellular Uptake of a Drug Delivery Vehicle Composed of an Integrin-Targeting Diketopiperazine Peptidomimetic and a Cell-Penetrating Peptide
Abstract
Cell-penetrating peptides (CPPs) have emerged as powerful tools in terms of drug delivery. Those short, often cationic peptides are characterized by their usually low toxicity and their ability to transport diverse cargos inside almost any kinds of cells. Still, one major drawback is their nonselective uptake making their application in targeted cancer therapies questionable. In this work, we aimed to combine the power of a CPP (sC18) with an integrin-targeting unit (c[DKP-f3-RGD]). The latter is composed of the Arg-Gly-Asp peptide sequence cyclized via a diketopiperazine scaffold and is characterized by its high selectivity toward integrin αvβ3. The two parts were linked via copper-catalyzed alkyne-azide click reaction (CuAAC), while the CPP was additionally functionalized with either a fluorescent dye or the anticancer drug daunorubicin. Both functionalities allowed a careful biological evaluation of these novel peptide-conjugates regarding their cellular uptake mechanism, as well as cytotoxicity in αvβ3 integrin receptor expressing cells versus cells that do not express αvβ3. Our results show that the uptake follows a "kiss-and-run"-like model, in which the conjugates first target and recognize the receptor, but translocate mainly by CPP mediation. Thereby, we observed significantly more pronounced toxic effects in αvβ3 expressing U87 cells compared to HT-29 and MCF-7 cells, when the cells were exposed to the substances with only very short contact times (15 min). All in all, we present new concepts for the design of cancer selective peptide-drug conjugates.
Similar articles
-
αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology.Curr Top Med Chem. 2016;16(3):314-29. doi: 10.2174/1568026615666150701114343. Curr Top Med Chem. 2016. PMID: 26126915 Review.
-
Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.Chemistry. 2015 Apr 27;21(18):6921-9. doi: 10.1002/chem.201500158. Epub 2015 Mar 17. Chemistry. 2015. PMID: 25784522
-
Cyclic isoDGR and RGD peptidomimetics containing bifunctional diketopiperazine scaffolds are integrin antagonists.Chemistry. 2015 Apr 13;21(16):6265-71. doi: 10.1002/chem.201406567. Epub 2015 Mar 11. Chemistry. 2015. PMID: 25761230
-
Design and Development of Polysaccharide-Doxorubicin-Peptide Bioconjugates for Dual Synergistic Effects of Integrin-Targeted and Cell-Penetrating Peptides for Cancer Chemotherapy.Bioconjug Chem. 2018 Jun 20;29(6):1973-2000. doi: 10.1021/acs.bioconjchem.8b00208. Epub 2018 May 30. Bioconjug Chem. 2018. PMID: 29790738
-
The Current Role of Cell-Penetrating Peptides in Cancer Therapy.Adv Exp Med Biol. 2017;1030:279-295. doi: 10.1007/978-3-319-66095-0_13. Adv Exp Med Biol. 2017. PMID: 29081059 Review.
Cited by
-
Cell-penetrating peptides improve pharmacokinetics and pharmacodynamics of anticancer drugs.Tissue Barriers. 2022 Jan 2;10(1):1965418. doi: 10.1080/21688370.2021.1965418. Epub 2021 Aug 17. Tissue Barriers. 2022. PMID: 34402743 Free PMC article. Review.
-
Optimizing the enzymatic release of MMAE from isoDGR-based small molecule drug conjugate by incorporation of a GPLG-PABC enzymatically cleavable linker.Front Pharmacol. 2023 Jul 10;14:1215694. doi: 10.3389/fphar.2023.1215694. eCollection 2023. Front Pharmacol. 2023. PMID: 37492088 Free PMC article.
-
Comparing Variants of the Cell-Penetrating Peptide sC18 to Design Peptide-Drug Conjugates.Molecules. 2022 Oct 7;27(19):6656. doi: 10.3390/molecules27196656. Molecules. 2022. PMID: 36235193 Free PMC article.
-
Cyclic RGD and isoDGR Integrin Ligands Containing cis-2-amino-1-cyclopentanecarboxylic (cis-β-ACPC) Scaffolds.Molecules. 2020 Dec 16;25(24):5966. doi: 10.3390/molecules25245966. Molecules. 2020. PMID: 33339382 Free PMC article.
-
Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?Acta Pharm Sin B. 2023 Feb;13(2):498-516. doi: 10.1016/j.apsb.2022.07.020. Epub 2022 Aug 3. Acta Pharm Sin B. 2023. PMID: 36873165 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous